SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit) June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine
Society for Integrative Oncology’s Post
More Relevant Posts
-
SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit) June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine
To view or add a comment, sign in
-
-
SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit) June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine
To view or add a comment, sign in
-
-
SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit) June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine
To view or add a comment, sign in
-
-
Reminder - SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit). June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine
To view or add a comment, sign in
-
-
Caught in the mid-day slump and struggling to refocus? Let’s fast-track the process and give your brain a dose of energy! Solve this week’s puzzle. Which piece completes the image? #PharmaChoice #Pharmacy#PharmaChoiceCanada #PharmacistsCare #CommunityPharmacy #YourPharmacy #PCH #PCC #LoveMyPharmacy #Pharmacy24
To view or add a comment, sign in
-
-
Epcortimab-bysp, as a single agent, demonstrated promising antitumor activity in high-risk patients with relapsed/refractory #CLL in the expansion cohort of the phase 1b/2 EPCORE CLL-1 trial. #lymsm https://lnkd.in/ena_m7B2
To view or add a comment, sign in
-
-
A long Journey for CT001, including four clinical trials, have now culminated with the development of a unified pediatric-adult model. Fantastic collaborative approach, thanks to all involved! Key Takeaways: ➡ The pain relief estimated for CT001 would be difficult to obtain with sufentanil alone in children and would likely require more than double the sufentanil exposure. Increasing sufentanil or ketamine exposure could lead to side-effects like respiratory depression or hallucinogenic effects. ➡ The simulated pain reduction in children using CT001 was 87% (76%/92%) with a 95% CI for n=37. In comparison, sufentanil alone showed 52% (34%/65%) pain reduction, ketamine alone showed 32% (12%/47%), and placebo showed a 10% (1%/20%) increase. #PediatricCare #PainManagement #ClinicalResearch #PKPD
Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.... Today is a great day for the company and CT001 - The data strongly support our hypothesis that CT001 is very effective in children relative to its active comparators and will be instrumental in our final development and commercialisation. https://lnkd.in/dfc5vU7Z
To view or add a comment, sign in
-
-
Did you miss our webinar on key considerations for Sample Sourcing? 💻🔬 You can now download our recording by clicking here ➡️: https://bit.ly/3IR0tjL Sample sourcing is critical to the delivery and success of your project. Take some time to learn from the experts at ARC in this bite sized webinar. Remember, you can always reach out to us directly if you have any questions: https://bit.ly/3TnXKDn 🌎 #TeamARC #CRO #IVD #CDx #PrecisionMedicine #ContractResearchOrganisation
To view or add a comment, sign in
-
Introducing the Vercise Cartesia™ Directional Lead and Standard Lead - key components of the Vercise Genus DBS System. Offering unparalleled precision and personalization in therapy, these leads are designed to enhance clinical outcomes while minimizing side effects. Explore how these leads are revolutionizing DBS therapy: https://lnkd.in/egpZDTRS #BSCEMEA #DeepBrainStimulation #DBS
Cartesia™ 3D Directional Programming Capabilities
To view or add a comment, sign in
-
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic crc : a phase 1 trial. 👉Orr was 17% 👉DCR was 61% 👉Median DOR was not reached 👉median PFS was 3.5 months
To view or add a comment, sign in
-
Putting my cancer experience to work to connect Patients, Advocates & Clinicians with Integrative Oncology
2moSave the date! Not a member? Consider this an opportunity to learn more about becoming one ;-)